Strategic Alliances (Details) - USD ($)						1 Months Ended		3 Months Ended								12 Months Ended			96 Months Ended
	Sep. 14, 2021	Jul. 06, 2021	Jun. 18, 2021	May 05, 2020	Oct. 21, 2019	May 31, 2016	Jan. 31, 2015	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues								$ 185,340,000	$ 179,744,000	$ 309,893,000	$ 329,219,000	$ 401,332,000	$ 385,813,000	$ 442,408,000	$ 545,165,000	$ 1,004,196,000	$ 1,774,718,000	$ 1,435,413,000
Contract liability								138,000				466,000				138,000	466,000		$ 138,000
Milestone revenue recognized																328,000
Transfer Of Intellectual Property And Other [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues																105,721,000	25,842,000	53,219,000
Transfer Of Intellectual Property And Other [Member] | Product registrations
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues				$ 3,000,000
Maximum milestone payments																		3,000,000
Product registrations
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues																142,845,000	141,770,000	119,952,000
LeaderMed | Transfer Of Intellectual Property And Other [Member] | Product registrations
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues																	1,000,000
LeaderMed | LenderMed Joint Venture | Corporate Joint Venture
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Ownership interest in joint venture (as a percent)	47.00%
Initial investment in joint venture	$ 11,000,000
Ownership percentage by related parties (as a percent)	53.00%
LeaderMed | LenderMed Joint Venture | Corporate Joint Venture | Transfer Of Intellectual Property And Other [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues	$ 1,000,000																1,000,000
CAMP4
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment (in shares)		3,373,008
Outstanding shares (as a percent)		9.00%
Period following first commercial sale in a country		10 years
CAMP4 | Transfer Of Intellectual Property And Other [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues		$ 1,500,000
CAMP4 | Transfer Of Intellectual Property And Other [Member] | Product registrations
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues																	4,900,000
CAMP4 | Dravet Syndrome Products
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Development milestone payments		3,500,000
Sales milestone payments		$ 90,000,000
Development milestone payments (in shares)		5,782,299
CAMP4 | Non-Dravet Syndrome Products
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Development milestone payments		$ 4,000,000
Sales milestone payments		$ 90,000,000
Development milestone payments (in shares)		1,082,248
Nicoya
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment from development and license agreement			$ 5,000,000
Proceeds including accrued interest for delayed payment			2,500,000
Proceeds from submission of investigational new drug			$ 2,500,000
Period after first commercial sale			10 years
Initial upfront payment																	5,000,000
Nicoya | Phase Three Initiation
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment from development and license agreement			$ 5,000,000
Nicoya | Regulatory and Development
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment from development and license agreement			$ 115,000,000
Nicoya | Transfer Of Intellectual Property And Other [Member] | Product registrations
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues																2,500,000
Vifor Fresenius Medical Care Pharma Ltd | Transfer Of Intellectual Property And Other [Member] | Product registrations
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues																3,000,000
Vifor Fresenius Medical Care Pharma Ltd | Exclusive Option
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum milestone payments						$ 555,000,000
Rayaldee | Regulatory Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum milestone payments				17,000,000
Rayaldee | Sales Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum milestone payments				$ 207,000,000
Pfizer | Product registrations
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum milestone payments							$ 275,000,000			$ 85,000,000
Milestone payments																85,000,000
Annual height velocity at point in time					12 months
Initial upfront payment							295,000,000
Contract liability								$ 0				$ 0				0	0		0
Additional milestone payment							275,000,000
Milestone revenue recognized																			$ 85,000,000
Pfizer | Product registrations | Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments							20,000,000
Pfizer | Product registrations | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments							$ 90,000,000
Pfizer | Transfer Of Intellectual Property And Other [Member] | Product registrations
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues																9,300,000	$ 10,800,000	$ 28,700,000
Maximum milestone payments																$ 85,000,000